Get started
Syros Pharmaceuticals, Inc.Syros Pharmaceuticals, Inc.Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonals

SEC filings and other documents


Explore the latest company documents and SEC filings from the company, including Forms 10-K, 10-Q, 8-K, and other key disclosures. Evaluate financial performance and operational updates to make more informed decisions.
2024
Earnings, Q3 FY2024
Oct 31, 2024
Pivotal Phase 3 data for tamibarotene in higher-risk MDS expected soon, with strong financial position.
H.C. Wainwright 26th Annual Global Investment Conference 2024
Sep 9, 2024
Pivotal phase III data for a first-in-class MDS therapy expected Q4 2024, with launch plans advancing.
Corporate Presentation
Sep 6, 2024
Pivotal Phase 3 data for tamibarotene in HR-MDS expected by mid-Q4 2024, with launch preparations underway.
Earnings, Q2 FY2024
Jul 31, 2024
Pivotal MDS and AML data for tamibarotene expected in late 2024, with strong cash runway.
Status Update
Jun 25, 2024
Pivotal data for tamibarotene in higher-risk MDS expected Q4 2024, with strong adoption potential.
TD Cowen 5th Annual Oncology Innovation Summit
May 29, 2024
The Citizens JMP Life Sciences Conference
May 14, 2024
Earnings, Q1 FY2024
May 14, 2024
TD Cowen 44th Annual Health Care Conference 2024
Mar 5, 2024
2023
Earnings, Q4 FY2023
Annual
Mar 27, 2024
The JMP Securities Hemaology and Oncology Summit
Dec 6, 2023
Study Result
Dec 6, 2023
Piper Sandler 35th Annual Healthcare Conference
Nov 28, 2023
Earnings, Q3 FY2023
Nov 14, 2023
Earnings, Q2 FY2023
Aug 8, 2023
Earnings, Q1 FY2023
May 10, 2023
2022
Earnings, Q4 FY2022
Annual
Mar 2, 2023
Status Update
Dec 10, 2022
Earnings, Q3 FY2022
Nov 14, 2022
Earnings, Q2 FY2022
Aug 9, 2022
M&A Announcement
Jul 5, 2022
Earnings, Q1 FY2022
May 16, 2022
2021
Earnings, Q4 FY2021
Annual
Mar 15, 2022
2020
Earnings, Q4 FY2020
Annual
Mar 4, 2021